Novartis adjusts business unit names in preparation for Sandoz generics and biosimilars spinoff

No­var­tis is mod­i­fy­ing its busi­ness units’ names to re­flect its full fo­cus on in­no­v­a­tive med­i­cines when San­doz spins off with gener­ics and biosim­i­lars lat­er this year.

Two di­vi­sions will drop the words “in­no­v­a­tive med­i­cines” from their names — go­ing from In­no­v­a­tive Med­i­cines In­ter­na­tion­al to In­ter­na­tion­al and from In­no­v­a­tive Med­i­cines US to sim­ply US. Re­search & ear­ly de­vel­op­ment will now be called Bio­med­ical Re­search, drop­ping one word from its cur­rent In­sti­tutes for Bio­Med­ical Re­search.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.